Pharmacologic inhibition of MEK1/2 reduces lung inflammation without impairing bacterial clearance in experimental Pseudomonas aeruginosa pneumonia

Pharmacologic inhibition of MEK1/2 reduces lung inflammation without impairing bacterial clearance in experimental Pseudomonas aeruginosa pneumonia

Abstract This study was designed to test the therapeutic potential of a MEK1/2 inhibitor (MEKi) in an experimental model of Pseudomonas aeruginosa pneumonia. The study found that treatment with MEKi reduced alveolar neutrophilic inflammation and led to faster recovery of weight compared to carrier-t...

Full description

Bibliographic Details
Main Authors: Matthew E. Long, Ke-Qin Gong, William E. Eddy, W. Conrad Liles, Anne M. Manicone
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Pneumonia
Subjects:
Macrophage
MEK1/2
Pseudomonas aeruginosa
Lung
Online Access:http://link.springer.com/article/10.1186/s41479-017-0037-y

Internet

http://link.springer.com/article/10.1186/s41479-017-0037-y

Similar Items